The company is actively seeking a Type A Meeting with the FDA to discuss the Investigational New Drug Application for CER-1236, which has been put on clinical hold due to two pharmacology and ...
Ahead of a Thursday advisory committee meeting, the FDA has raised questions about the broad use of PD-1 inhibitors in gastric adenocarcinoma, pointing to the potential need to limit ...